LPL Financial LLC Has $6.50 Million Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

LPL Financial LLC grew its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 12.4% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 53,438 shares of the biotechnology company's stock after purchasing an additional 5,895 shares during the period. LPL Financial LLC owned about 0.06% of Sarepta Therapeutics worth $6,497,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in SRPT. Charles Schwab Investment Management Inc. lifted its position in shares of Sarepta Therapeutics by 2.0% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 623,749 shares of the biotechnology company's stock worth $75,842,000 after purchasing an additional 12,000 shares in the last quarter. Proficio Capital Partners LLC acquired a new position in shares of Sarepta Therapeutics during the fourth quarter valued at $3,829,000. Geode Capital Management LLC boosted its holdings in Sarepta Therapeutics by 2.7% in the third quarter. Geode Capital Management LLC now owns 1,696,354 shares of the biotechnology company's stock valued at $211,910,000 after acquiring an additional 44,306 shares during the last quarter. Nordea Investment Management AB increased its position in Sarepta Therapeutics by 19.1% in the fourth quarter. Nordea Investment Management AB now owns 67,546 shares of the biotechnology company's stock worth $8,228,000 after purchasing an additional 10,815 shares during the period. Finally, Allspring Global Investments Holdings LLC raised its holdings in Sarepta Therapeutics by 16,717.7% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 85,434 shares of the biotechnology company's stock worth $10,602,000 after purchasing an additional 84,926 shares during the last quarter. Institutional investors own 86.68% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

SRPT has been the subject of several analyst reports. Royal Bank of Canada cut shares of Sarepta Therapeutics from an "outperform" rating to a "sector perform" rating and lowered their price target for the stock from $161.00 to $87.00 in a research report on Monday, March 31st. Wells Fargo & Company assumed coverage on shares of Sarepta Therapeutics in a report on Friday. They set an "overweight" rating and a $115.00 target price for the company. Cantor Fitzgerald reissued an "overweight" rating and issued a $163.00 price target on shares of Sarepta Therapeutics in a research note on Tuesday, March 18th. Morgan Stanley decreased their price objective on Sarepta Therapeutics from $196.00 to $182.00 and set an "overweight" rating for the company in a research note on Friday. Finally, HC Wainwright raised Sarepta Therapeutics from a "sell" rating to a "neutral" rating and set a $75.00 target price on the stock in a research note on Wednesday, April 2nd. Six analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $161.83.

Insider Buying and Selling

In related news, Director Claude Nicaise sold 2,491 shares of Sarepta Therapeutics stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total value of $248,203.24. Following the sale, the director now owns 27,812 shares of the company's stock, valued at approximately $2,771,187.68. The trade was a 8.22 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 7.70% of the stock is currently owned by corporate insiders.

Sarepta Therapeutics Stock Up 1.4 %

NASDAQ:SRPT traded up $0.72 during trading hours on Friday, reaching $51.03. 4,036,516 shares of the stock were exchanged, compared to its average volume of 1,388,097. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. Sarepta Therapeutics, Inc. has a twelve month low of $48.01 and a twelve month high of $173.25. The stock has a market cap of $4.95 billion, a PE ratio of 40.82 and a beta of 0.93. The firm has a 50 day moving average of $88.11 and a 200 day moving average of $110.20.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.